Chroma Medicine Secures $135M in Series B Financing to Advance Breakthrough Epigenetic Editing Technology and Expand Pipeline of Durable Precision Genomic Medicines

Funding to progress Chroma's single-dose epigenetic editing therapies and support expansion of novel genetic medicine platform designed to enable precise gene regulation while preserving genomic integrity Financing led by GV, with participation from ARC... Biopharmaceuticals, Venture Capital Chroma Medicine, genomic medicine, epigenetic editing
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news